Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY-Outcomes: Retatrutide in MASLD With High Risk of Major Adverse Liver Outcomes (ISA2, China)
CTR20255050Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of retatrutide in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Eli Lilly and Company. Started Feb 2026; status: active.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on CTR20255050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255050.